On February 27, 2026, William Blair upgraded Biodesix’s (NasdaqGM:BDSX) outlook from Market Perform to Outperform, with an average one-year price target set at $33.15/share—representing a potential upside of 116.24% from the last closing price of $15.33/share.
The projected annual revenue for Biodesix is $94 million, a 16.68% increase year-over-year. As of recent reports, institutional ownership decreased by 13.89% to 31 funds, while total shares owned rose by 4.79% to 1,342K shares. The put/call ratio stands at 0.10, indicating a bullish market sentiment.
